XML 19 R3.htm IDEA: XBRL DOCUMENT v3.22.4
Consolidated Balance Sheets - USD ($)
Dec. 31, 2022
Dec. 31, 2021
Current assets:    
Cash and cash equivalents $ 46,329,359 $ 71,143,778
Short-term investments 206,669,397 330,170,940
Accounts receivable 1,701,726 5,466,850
Accounts receivable from affiliated entities 10,036,490 2,565,194
Prepaid expenses and other current assets 50,130,481 38,836,991
Prepaid expenses and other current assets from affiliated entities 375,227 261,192
Total current assets 315,242,680 448,444,945
Fixed assets, net 7,727,997 17,453,206
Investments in affiliated entity 2,007,142 3,906,796
Intangible assets, net 2,129,861 2,626,355
Goodwill 10,513,371 10,513,371
Operating lease right-of-use assets 10,228,207 11,571,026
Other assets 684,044 1,425,794
Total assets 348,533,302 495,941,493
Current liabilities:    
Accounts payable and accrued expenses 79,686,885 47,644,530
Accounts payable and accrued expenses due to affiliated entities 1,220,439 548,032
Accrued clinical trial expenses 10,594,073 10,326,266
Deferred revenue 0 21,628
Operating lease liability 2,803,973 2,603,956
Grant funding liability 2,475,031 4,559,721
Grant funding liability from affiliated entities 87,673 37,500
Total current liabilities 96,868,074 65,741,633
Deferred revenue, net of current portion 0 64,361
Operating lease liability, net of current portion 12,655,586 15,459,559
Deferred tax liabilities 32,046 32,046
Other liabilities 0 14,826
Total liabilities 126,170,546 96,272,072
Commitments and contingencies
Inovio Pharmaceuticals, Inc. stockholders’ equity:    
Preferred stock—par value $0.001; Authorized shares: 10,000,000, issued and outstanding shares: 9 at December 31, 2022 and 2021 0 0
Common stock—par value $0.001; Authorized shares: 600,000,000 at December 31, 2022 and 2021, issued and outstanding: 253,091,319 at December 31, 2022 and 217,382,887 at December 31, 2021 253,090 217,382
Additional paid-in capital 1,710,656,191 1,609,589,797
Accumulated deficit (1,487,847,784) (1,209,855,522)
Accumulated other comprehensive loss (698,741) (282,236)
Total Inovio Pharmaceuticals, Inc. stockholders’ equity 222,362,756 399,669,421
Total liabilities and stockholders’ equity 348,533,302 495,941,493
6.50% Convertible Senior Notes Due 2024    
Current liabilities:    
Convertible senior notes $ 16,614,840 $ 14,959,647